Endometriosis Patients Undergoing Quinagolide Treatment

This study has been completed.

First Received: February 20, 2008 Last Updated: January 9, 2009 History of Changes

Sponsored by:	Instituto Valenciano de Infertilidad, Spain
Information provided by:	Instituto Valenciano de Infertilidad, Spain
ClinicalTrials.gov Identifier:	NCT00625950

Purpose

Dopamine agonists, such as quinagolide, are able to act on the VEGFR-2 blocking antibodies, diminishing Vascular Endothelial Growth Factor effect on angiogenesis in human endometriotic lesions.

Condition	Intervention	Phase
Hyperprolactinemia Endometriosis	Procedure: ENDOMETRIAL BIOPSY	Phase IV

Study Type:	Interventional
Study Design:	Health Services Research, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Efficacy Study
Official Title:	Effect of Treatment With Agonist Dopaminergics on Endometriosic Lesions.

Resource links provided by NLM:

MedlinePlus related topics: Endometriosis

U.S. FDA Resources

Further study details as provided by Instituto Valenciano de Infertilidad, Spain:

Primary Outcome Measures:

observation of three month treatment with Quinagolida in endometriosis patients [ Time Frame: onset and three months after onset ] [ Designated as safety issue: No ]

Estimated Enrollment:	5
Study Start Date:	February 2008
Study Completion Date:	May 2008
Primary Completion Date:	April 2008 (Final data collection date for primary outcome measure)

Intervention Details:

Two routine laparoscopies in period of three months with endometrial biopsy comparative study performed.

Eligibility

Ages Eligible for Study:	18 Years to 37 Years
Genders Eligible for Study:	Female
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Hyperprolactinemia
Unexplained infertility
Endometriosis

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00625950

Locations

Spain
Instituto Valenciano de Infertilidad
Valencia, Spain, 46015

Sponsors and Collaborators

Instituto Valenciano de Infertilidad, Spain

More Information

No publications provided

Responsible Party:	Instituto Valenciano de Infertilidad, Spain ( Prof. Dr. Antonio Pellicer )
Study ID Numbers:	VLC-AP-10208-208-1
Study First Received:	February 20, 2008
Last Updated:	January 9, 2009
ClinicalTrials.gov Identifier:	NCT00625950 History of Changes
Health Authority:	Spain: Ethics Committee

Keywords provided by Instituto Valenciano de Infertilidad, Spain:

Hyperprolactinemia
Endometriosis
laparoscopy
angiogenesis, VEGF

Study placed in the following topic categories:

Hypothalamic Diseases
Quinagolide
Pituitary Diseases
Central Nervous System Diseases
Endocrine System Diseases
Endometriosis
Brain Diseases

Dopamine Agonists
Genital Diseases, Female
Dopamine
Galactorrhoea-Hyperprolactinaemia
Hyperprolactinemia
Dopamine Agents
Endocrinopathy

Additional relevant MeSH terms:

Genital Diseases, Female
Hypothalamic Diseases
Hyperpituitarism
Pituitary Diseases
Nervous System Diseases

Endocrine System Diseases
Central Nervous System Diseases
Hyperprolactinemia
Endometriosis
Brain Diseases

ClinicalTrials.gov processed this record on September 04, 2009